Renal Cell Carcinoma
Renal Cell Carcinoma
Advertisement
Emily MenendezRenal Cell Carcinoma Diagnostics | June 12, 2024
The use of 89Zr PET/CT and subsequent surgery in patients treated with it demonstrated low radiation exposure levels.
Read More
Karine Tawagi, MDAdvancements in Oncology | June 12, 2024
Dr. Tawagi considers how "favorable" and "very favorable" risk alters her approach to patient management for aRCC.
Andrea B. Apolo, MDTesticular, Penile, and Rare Malignancies | June 12, 2024
Dr. Apolo shares the trials in progress she presented at this year's meeting, including SMART, LASER, and E-VIRTUE.
Tian Zhang, MDAdvanced Renal Cell Carcinoma | June 10, 2024
Dr. Zhang highlights the results of a phase 2 trial for sequential treatment of cabozantinib in advanced RCC.
Laurence Albiges, MD, PhDnccRCC | June 10, 2024
Dr. Albiges comments on the latest data from the nccRCC trial KEYNOTE-B61, including an extended follow-up analysis.
Laurence Albiges, MD, PhDLocalized Renal Cell Carcinoma | June 10, 2024
Dr. Albiges breaks down a biomarker analysis of circulating kidney injury molecule-1 in the IMmotion010 trial.
GU Oncology Now EditorsAdvancements in Oncology | June 6, 2024
The discussion focused on advanced and metastatic stages of RCC, shedding light on current practices in clinics.
Manmeet Ahluwalia, MD, MBA, FASCOAdvanced Renal Cell Carcinoma | June 10, 2024
The combination of SRS with IO significantly increases the OS in RCCBM compared with IO, WBRT, or WBRT plus IO.
Katy MarshallRenal Cell Carcinoma | June 7, 2024
KIM-1 levels were evaluated using a high-sensitivity electrochemiluminescence assay.
Brandon TwyfordAdvanced Renal Cell Carcinoma | June 10, 2024
The KEYNOTE-426 study explored pembrolizumab and axitinib vs sunitinib in advanced RCC using genetic biomarkers.
Karl Semaan, MDAdvanced Renal Cell Carcinoma | June 5, 2024
Drs. Semaan and El Zarif detail an investigation into first-line systemic therapy following adjuvant immunotherapy for RCC.
Viktor Grünwald, MD, PhDAdvanced Renal Cell Carcinoma | June 5, 2024
Dr. Grünwald showcases patterns of progression and subsequent therapy for patients receiving len/pembro for aRCC.
Sahil Doshi, MDnccRCC | June 5, 2024
The study sought to better understand the effects of first-line systemic therapy in metastatic ChRCC.
Charles Nguyen, MDnccRCC | June 7, 2024
Dr. Nguyen shares an ongoing study of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma.
Emily MenendezAdvanced Renal Cell Carcinoma | June 10, 2024
The trial previously demonstrated longer PFS rates with avelumab plus axitinib in patients with PD-L1-positive tumors.
Emily MenendezRenal Cell Carcinoma | June 7, 2024
New results of CheckMate 67T focused on additional safety analyses and patient-reported outcomes.
Emily MenendezAdvanced Renal Cell Carcinoma | June 10, 2024
Patients who received lenvatinib plus pembrolizumab experienced later progression across tumors in multiple organs.
Zachary BessetteAdvanced Renal Cell Carcinoma | June 10, 2024
Patients with RCC who experience disease recurrence after adjuvant IO benefit from subsequent systemic therapies.
Katy MarshallAdvanced Renal Cell Carcinoma | June 7, 2024
Investigators found that the median follow-up period was 16.5 months at the study’s cutoff date.
Zachary BessettenccRCC | June 7, 2024
Dr. Doshi and colleagues designed an analysis of patients with metastatic ChRCC to better understand first-line therapy.
Advertisement
Advertisement
Advertisement